PharmaPoint: Dermatophytic Onychomycosis (DO) - US Drug Forecast and Market Analysis to 2022

189 views
146 views

Published on

Dermatophytic onychomycosis (DO) is characterized as being a fungal infection of the nail. Infection can involve the nail unit (nail matrix, nail bed, or nail plate). DO isn’t considered life-threatening, however can cause patients to experience discomfort, pain, and may cause physical and occupational limitations. DO patients can be identified as having thick or brittle nails along with discoloration (white and opaque). Physicians currently use direct microscopy and fungal culture tests to ensure correct diagnosis and treatment are achieved.

Published in: Business, Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
189
On SlideShare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
1
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

PharmaPoint: Dermatophytic Onychomycosis (DO) - US Drug Forecast and Market Analysis to 2022

  1. 1. PharmaPoint: Dermatophytic Onychomycosis (DO) - US Drug Forecast and Market Analysis to 2022Dermatophytic onychomycosis (DO) is characterized as being a fungal infection of the nail. Infection caninvolve the nail unit (nail matrix, nail bed, or nail plate). DO isn’t considered life-threatening, howevercan cause patients to experience discomfort, pain, and may cause physical and occupational limitations. DOpatients can be identified as having thick or brittle nails along with discoloration (white and opaque).Physicians currently use direct microscopy and fungal culture tests to ensure correct diagnosis and treatmentare achieved.Risk factors such as advanced age, pre-existing diabetes, or immunocompromised systems can increase theincidence of DO in patients. Current therapies consist of generics that offer substantial efficacy but sub-parsafety profiles. A new wave of therapies is expected to offer topical options for patients who are unable towithstand existing generic options. These therapies are also expected to drive an increase in total drugtreatment rates in the US market.ScopeOverview of DO, including epidemiology, etiology, general symptoms from infection, and diseasemanagement recommendations and guidelines. Annualized DO market revenue, annual cost of therapy andtreatment usage pattern data from 2012 and forecast for ten years to 2022. Key topics covered include strategiccompetitor assessment, market characterization, unmet needs, clinical trial mapping and implications for theDO market. Pipeline analysis: comprehensive data split across different phases, and emerging trends,specifically new therapies with novel routes of administration. Analysis of the current and future marketcompetition in the US DO market. Insightful review of the key industry and governmental drivers, restraintsand challenges. Each trend is independently researched to provide qualitative analysis of its implications.Market Model FeaturesAn interactive excel forecast model based on primary research interviews and surveys with KOLs andhigh-prescribing physicians is included in this report*. This patient based model provides diagnosis rates,patient segmentation, treatment rates, annual costs of therapy , and indication-specific drug sales for the 10year forecast period. The forecast model is robust, fully transparent, and easy to navigate. Moreover, ourmodels support data presented in the reports and the complete methodology is outlined in the report and themodel.*Model only available with site and global license purchases.Key FindingsGeneric therapies are expected to pose as a considerable threat to upcoming topical therapies because oftheir shorter treatment duration. The first wave of new pipeline candidates will increase drug treatment rates asphysicians begin to opt for more safer options for treatment. Individual compliance, patient co-morbidities,and insurance payers function as important considerations in assessing the treatment algorithm for everypatient.Key Questions Answered in this ReportHow big of an impact will topical agents have on the DO market? What do key opinion leaders think of thisparadigm shift? What new product is expected to become the market leader during the forecast period? Howwill this impact the existing generic therapies? How will a change in the route of administration change thePharmaPoint: Dermatophytic Onychomycosis (DO) - US Drug Forecast and Market Analysis to 2022
  2. 2. uptake of drugs in the US market? What are the primary unmet needs that exist in the market according to keyopinion leaders? What alliance opportunities exist in this market for a company looking to tap into the DOmarket?Key BenefitsDevelop and design your in-licensing and out-licensing strategies through a review of pipeline products andtechnologies, and by identifying the companies with the most robust pipeline. Develop business strategies byunderstanding the trends shaping and driving the US DO market. Drive revenues by understanding the keytrends, innovative products and technologies, market segments, and companies likely to impact the US DOmarket in future. Formulate effective sales and marketing strategies by understanding the competitivelandscape and by analyzing the performance of various competitors. Identify emerging players withpotentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.Track drug sales in the US DO market from 2012-2022. Organize your sales and marketing efforts byidentifying the market categories and segments that present maximum opportunities for consolidations,investments and strategic partnerships.table Of Contents1 Table Of Contents1.1 List Of Tables1.2 List Of Figures2 Introduction2.1 Catalyst2.2 Related Reports2.3 Upcoming Related Reports3 Disease Overview3.1 Etiology And Pathophysiology3.1.1 Etiology3.1.2 Pathophysiology3.1.3 Prognosis3.1.4 Quality Of Life3.2 Symptoms4 Epidemiology4.1 Risk Factors And Comorbidities4.1.1 Poor Peripheral Circulation Is Greater In Older Men4.1.2 Household Contact With Other Do Patients Increases Risk Of Infection 2.5 Times4.1.3 Immunosuppression Increases Susceptibility To Do InfectionsPharmaPoint: Dermatophytic Onychomycosis (DO) - US Drug Forecast and Market Analysis to 2022
  3. 3. 4.1.4 Prevalence Of Dermatophytic Onychomycosis Is Higher In Diabetics Than Innon-diabetics4.2 Global Trends4.3 Forecast Methodology4.3.1 Sources Used4.3.2 Forecast Assumptions And Methods4.3.3 Sources Not Used4.4 Epidemiology Forecast (2012–2022)4.4.1 Prevalent Cases Of Dermatophytic Onychomycosis4.4.2 Age-specific Prevalent Cases Of Dermatophytic Onychomycosis4.4.3 Sex-specific Prevalent Cases Of Dermatophytic Onychomycosis4.5 Discussion4.5.1 Epidemiological Trends4.5.2 Limitations Of The Analysis4.5.3 Strengths Of The Analysis5 Disease Management5.1 Treatment Overview5.1.1 Diagnosis5.1.2 Clinical Practice6 Competitive Assessment6.1 Overview6.2 Strategic Competitor Assessment6.3 Product Profiles6.3.1 Terbinafine6.3.2 Itraconazole6.3.3 Fluconazole6.3.4 Ketoconazole6.3.5 Griseofulvin6.3.6 Ciclopirox7 Opportunity And Unmet Need7.1 Overview7.2 Unmet Needs7.2.1 Unmet Need: Efficacious Oral And Topical Treatments7.2.2 Unmet Need: Clinical Safety7.2.3 Unmet Need: Patient Awareness7.2.4 Unmet Need: Shorter Treatment Duration7.2.5 Unmet Need: Higher Treatment RatesPharmaPoint: Dermatophytic Onychomycosis (DO) - US Drug Forecast and Market Analysis to 2022
  4. 4. 7.2.6 Unmet Need: Prescribing Guidelines7.2.7 Unmet Need: Differential Diagnosis7.3 Unmet Needs Gap Analysis7.4 Opportunities7.4.1 Opportunity: Decreased Frequency Of Dosing7.4.2 Opportunity: Combinatorial Approaches To Treatment8 Clinical Pipeline Assessment8.1 Overview8.2 Clinical Trials By Phase And Trial Status8.3 Promising Drugs In Clinical Development8.3.1 Efinaconazole8.3.2 Tavaborole8.3.3 Tdt-0678.3.4 Luliconazole8.3.5 Albaconazole9 Current And Future Players9.1 Overview9.2 Trends In Corporate Strategy9.3 Company Profiles9.3.1 Valeant Pharmaceuticals International9.3.2 Topica Pharmaceuticals9.3.3 Anacor Pharmaceuticals9.4 Late-stage Competition9.4.1 Celtic Pharmaceutical Holdings9.4.2 Palau Pharma9.5 Early-stage Competition9.5.1 Merck9.5.2 Apricus Biosciences10 Market Outlook10.1 United States10.1.1 Forecast10.1.2 Key Events10.1.3 Drivers And Barriers11 Appendix11.1 BibliographyPharmaPoint: Dermatophytic Onychomycosis (DO) - US Drug Forecast and Market Analysis to 2022
  5. 5. 11.2 Abbreviations11.3 Methodology11.4 Forecasting Methodology11.4.1 Diagnosed Do Patients11.4.2 Percent Drug-treated Patients11.4.3 Drugs Included In Each Therapeutic Class11.4.4 Launch And Patent Expiry Dates11.4.5 General Pricing Assumptions11.4.6 Individual Drug Assumptions11.4.7 Pricing Of Pipeline Agents11.5 Physicians And Specialists Included In This Study11.6 About The Authors11.6.1 Author11.6.2 Reviewer11.6.3 Epidemiologist11.6.4 Global Head Of Healthcare11.7 About Globaldata11.8 Contact Us11.9 DisclaimerResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market researchreports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with ourhuge collection of market research reports. We provide our services to all sizes of organizations and across allindustry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well aspublishers and will assist you in making an informed decision by giving you unbiased and deep insights onwhich reports will satisfy your needs at the best price.Contact:M/s Sheela,90 State Street,Suite 700,Albany NY - 12207United StatesTel: +1-518-618-1030USA - Canada Toll Free 866-997-4948Email: sales@researchmoz.usWebsite: http://www.researchmoz.us/PharmaPoint: Dermatophytic Onychomycosis (DO) - US Drug Forecast and Market Analysis to 2022

×